TBK1 and hepatocellular carcinoma: Sorafenib, commonly used as a chemotherapeutic agent for HCC treatment, relies on autophagy-mediated degradation of key components in the MAVs-STING-TBK1-IFN-I pathway and the inhibition of type I IFN production by modulating the interaction between IRF3 and splicing proteins.